Chimeric antigen receptor T cell (CAR-T) therapy has transformed hematological cancer treatment, but its broader clinical application remains constrained by the exorbitant costs and complex procedures of ex vivo manufacturing. To overcome these limitations, in vivo CAR-T engineering strategies are emerging as compelling alternatives, enabling direct reprogramming of T cells within the patients. Recent studies indicate that in vivo CAR-T therapy is evolving from a delivery-centered concept into an integrated engineering framework that should coordinate cell-selective targeting, controllable CAR expression, T-cell fitness, and long-term safety. Looking forward, this field is likely to move beyond vector innovation alone toward multidimensional platform design, which is comprehensively discussed in this perspective.
- Open Access
- Perspective
From Ex Vivo to In Vivo: The Next Generation of CAR-T Therapy
Author Information
Received: 14 May 2026 | Revised: 31 May 2026 | Accepted: 13 October 2026 | Published: 27 October 2026
Abstract
References
- 1.
Singh, N.; Orlando, E.; Xu, J.; et al. Mechanisms of resistance to CAR T cell therapies. Semin. Cancer Biol. 2020, 65, 91–98. https://doi.org/10.1016/j.semcancer.2019.12.002.
- 2.
Parayath, N.N.; Stephan, M.T. In Situ Programming of CAR T Cells. Annu. Rev. Biomed. Eng. 2021, 23, 385–405. https://doi.org/10.1146/annurev-bioeng-070620-033348.
- 3.
Alhallak, K.; Sun, J.; Muz, B.; et al. Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. Oncotarget 2021, 12, 1878–1885. https://doi.org/10.18632/oncotarget.28054.
- 4.
Ellis, G.I.; Sheppard, N.C.; Riley, J.L. Genetic engineering of T cells for immunotherapy. Nat. Rev. Genet. 2021, 22, 427–447. https://doi.org/10.1038/s41576-021-00329-9.
- 5.
Li, Y.R.; Zhu, Y.; Yang, L. Clinical technology advances driving in vivo CAR therapy. Trends Biotechnol. 2026, 44, 1821–1824. https://doi.org/10.1016/j.tibtech.2025.11.006.
- 6.
Aalipour, A.; Barreiro, A.; Garmilla, A.; et al. In vivo CAR T cell engineering: Design principles and open questions. Trends Cancer 2026, 12, 434–446. https://doi.org/10.1016/j.trecan.2026.01.007.
- 7.
Hunter, T.L.; Bao, Y.; Zhang, Y.; et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 2025, 388, 1311–1317. https://doi.org/10.1126/science.ads8473.
- 8.
Gattinoni, L.; Inchingolo, G.; Harrer, D.C.; et al. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell 2026, 189, 3686–3700.e10. https://doi.org/10.1016/j.cell.2026.03.047.
- 9.
Nyberg, W.A.; Bernard, P.L.; Ngo, W.; et al. In vivo site-specific engineering to reprogram T cells. Nature 2026, 652, 712–721. https://doi.org/10.1038/s41586-026-10235-x.
- 10.
Zugasti, I.; Espinosa-Aroca, L.; Fidyt, K.; et al. CAR-T cell therapy for cancer: Current challenges and future directions. Signal Transduct. Target. Ther. 2025, 10, 210. https://doi.org/10.1038/s41392-025-02269-w.
- 11.
Chauhan, V.P.; Sharp, P.A.; Langer, R. Engineered prime editors with minimal genomic errors. Nature 2025, 646, 1254–1260. https://doi.org/10.1038/s41586-025-09537-3.
- 12.
An, N.; Wang, D.; Zhang, P.; et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study. Nat. Med. 2026, 32, 1257–1266. https://doi.org/10.1038/s41591-026-04244-6.
This work is licensed under a Creative Commons Attribution 4.0 International License.
